Patent application number | Description | Published |
20090017035 | HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4 - An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The human anti-hDll4 antibody or antibody fragment binds hDll4 with an affinity of 300 pM or better, as measured by surface plasmon resonance. | 01-15-2009 |
20090142354 | HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4 - An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The human anti-hDll4 antibody or antibody fragment binds dimeric hDll4 with an affinity of 75 pM or better, as measured by surface plasmon resonance. | 06-04-2009 |
20090246199 | THERAPEUTIC METHODS FOR INHIBITING TUMOR GROWTH WITH DLL4 ANTAGONISTS - Disclosed is a therapeutic method for inhibiting development or growth of tumors that are resistant to the blockade of delta-like ligand 4 (Dll4), or vascular endothelial growth factor (VEGF), or to other therapeutic agents, by administering the combination of Dll4 antagonist and VEGF antagonist. The combined administration of these two agents, concurrently or sequentially, exhibits synergistic effects on blood vessel development and growth, thereby more effectively inhibiting the tumor growth than an administration of either agent alone. The Dll4 antagonist can be an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor, or a fusion protein comprising the extracellular domain of Dll4 or a soluble Notch receptor, or a fragment thereof, fused to a multimerizing component. The VEGF antagonist can be a VEGF trap, anti-VEGF antibody or antibody fragment capable of inhibiting the binding of VEGF to a VEGF receptor. | 10-01-2009 |
20100330106 | Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent - The invention provides methods for treating various types of cancer/tumor by administering the combination of DII4 antagonists, in particular, DII4 antibodies and fragments thereof that specifically bind human DII4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing DII4 antagonists and chemotherapeutic agents are also provided. | 12-30-2010 |
20110027286 | High Affinity Human Antibodies to Human Angiopoietin-2 - The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis. | 02-03-2011 |
20110150905 | HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4 - The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the K | 06-23-2011 |
20120189635 | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) - The present invention provides methods for treating or preventing malaria by administering to a patient in need thereof a pharmaceutical composition comprising an antibody that specifically binds human angiopoietin-2 (Ang-2). | 07-26-2012 |
20130129722 | Methods for Treating Cancer by Administering an Anti-Ang-2 Antibody - The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis. | 05-23-2013 |
20130209492 | Anti-Tie2 Antibodies and Uses Thereof - The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis. | 08-15-2013 |
20130302356 | Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent - The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided. | 11-14-2013 |
20140112930 | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) - The present invention provides methods for treating or preventing malaria by administering to a patient in need thereof a pharmaceutical composition comprising an antibody that specifically binds human angiopoietin-2 (Ang-2). | 04-24-2014 |
20150147342 | Methods for Treating Cancer by Administering an Anti-Ang-2 Antibody - The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis. | 05-28-2015 |
20150152177 | High Affinity Human Antibodies to Human Angiopoietin-2 - The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis. | 06-04-2015 |
20150232545 | HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4 - The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the K | 08-20-2015 |
Patent application number | Description | Published |
20130344093 | Anti-EGFR Antibodies and Uses Thereof - The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth of tumor cells expressing high levels of EGFR and/or inducing antibody-dependent cell-mediated cytotoxicity (ADCC) of such cells. The antibodies of the invention are useful for the treatment of various cancers as well as other EGFR-related disorders. | 12-26-2013 |
20140308370 | MARKERS OF TUMOR CELL RESPONSE TO ANTI-CANCER THERAPY - Compositions and methods for determining circulating biomolecules before, during, and/or after treatment of a patient with an anti-cancer or anti-tumor drug (or putative drug) are described. Methods of treatments based on the compositions and methods described herein are also provided. Noninvasive methods and kits are provided for assessing the efficacy of an anti-cancer therapy for killing or damaging cancer cells. Embodiments are used to determine the cancer-killing efficacy of an anti-cancer drug in a patient, to optimize the selection of an anti-cancer drug for treatment of a patient, to adjust the dosage of an anti-cancer drug for treatment of a particular cancer in a patient and for identifying useful anti-cancer therapeutics for any one particular type of cancer. | 10-16-2014 |
20150056221 | ANTI-PRLR ANTIBODIES AND USES THEREOF - The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders. The present invention also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent. | 02-26-2015 |
20150056222 | ANTI-PRLR ANTIBODIES AND USES THEREOF - The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. According to certain embodiments, the invention includes antibodies that bind to the first fibronectin-like type III domain of the extracellular domain of PRLR. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders. The present invention also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent. | 02-26-2015 |
20150064189 | Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent - The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided. | 03-05-2015 |
20150191534 | HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4 - The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the K | 07-09-2015 |
20150197578 | Anti-Tie2 Antibodies and Uses Thereof - The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis. | 07-16-2015 |
20150203579 | Human Antibodies to PD-1 - The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder. | 07-23-2015 |
20150203580 | Human Antibodies to PD-L1 - The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection. | 07-23-2015 |
20150259423 | ANTI-EGFRvIII ANTIBODIES AND USES THEREOF - The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers. | 09-17-2015 |
20150266966 | Methods and Antibody Compositions for Tumor Treatment - The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fcγ receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fcγ receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders. | 09-24-2015 |
20150337043 | Anti-EGFR Antibodies and Uses Thereof - The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth of tumor cells expressing high levels of EGFR and/or inducing antibody-dependent cell-mediated cytotoxicity (ADCC) of such cells. The antibodies of the invention are useful for the treatment of various cancers as well as other EGFR-related disorders. | 11-26-2015 |
Patent application number | Description | Published |
20090240390 | SYSTEM AND METHOD FOR COMPONENT MONITORING - The health of components of an asset is proactively monitored. A sensor network provides a collection of metrics from a plurality of components of an asset. The collection of metrics includes a set of metrics corresponding to each component, and the set of metrics measures at least one operating characteristic, e.g. temperature, of the corresponding component. A component algorithm processing system receives the collection of metrics and determines a relationship between each set of metrics corresponding to each component and the collection of metrics corresponding to the plurality of components. The component algorithm processing system determines if the relationships indicate a health problem with at least one of the components. The metrics can be further analyzed to determine sensor faults, the remaining life, and the short-term and long-term health of each component. For example, the monitoring system can be applied to the plurality of planetaries on a light armored vehicle. | 09-24-2009 |
20090240467 | Sensor fault detection systems and methods thereof - A method, computer readable medium and system for detecting a sensor fault includes identifying one or more of a plurality of tools to use with at least one of a plurality of data acquisition systems based on data obtained from and at least one characteristic of the at least one of the data acquisition systems. The identified one or more tools are utilized on the obtained data to determine at least one confidence rating. An operational status for the at least one of the data acquisition systems is determined and provided based on at least the one determined confidence rating. | 09-24-2009 |
20090240469 | DYNAMIC DISPLAY SYSTEMS AND METHODS THEREOF - A method and system for displaying asset health information includes determining a status of at least one asset in a monitored system based on operational information obtained about the at least one asset. The obtained operational information about the at least one asset is compared against other operational information obtained about the monitored system. A review of the determined status of the at least one asset is conducted based on the comparison. At least one of textual information and numeric information is displayed based on the conducted review of the determined status of the at least one asset. Additionally, at least one of three or more indicator lights is displayed based on the conductive review of the determined status of the at least one asset. | 09-24-2009 |
20090240472 | DATA PROCESSING SYSTEMS AND METHODS - An Asset Health Management system monitors and analyzes the health of a component of an asset. A sensor network, with one or more sensors operably coupled to an asset component, collects sensor data associated with operating characteristics of the asset component. A processing node (a System Health Node) includes one or more modules, i.e., software functions, and one or more configuration files. The processing node processes the sensor data with the one or more modules according to the one or more configuration files and determines health information corresponding to the asset component. The one or more modules receive and transmit input and output data, respectively, via data streams that organize the input and output data, e.g., according to time stamps and that may be cached. The health information may be displayed on user interfaces and/or may be transmitted over an information network to external systems. | 09-24-2009 |
20090240604 | Method and apparatus for data acquisition in an asset health management system - An asset management system includes a controller area network bus and a data acquisition module connected to the controller area network bus. The data acquisition module has a plurality of analog input channels. One or more sensor systems are connected to the input channels with the input channels receiving analog signals from the sensor systems. The data acquisition module passively conditions the received analog signals prior to digital conversion. | 09-24-2009 |